Lumos Pharma (LUMO – Research Report) received a Buy rating and a $34.00 price target from JonesTrading analyst Lina Kaminski
Author: Bryan Anderson
Nvidia (NVDA) Received its Third Buy in a Row
After Merrill Lynch and Credit Suisse gave Nvidia (NASDAQ: NVDA) a Buy rating last month, the company received another Buy,
Why Did BTIG Upgrade Intersect ENT’s Stock?
Intersect ENT (XENT – Research Report) received a Buy rating and a $32.00 price target from BTIG analyst Ryan Zimmerman
Oppenheimer Believes Nvidia (NASDAQ: NVDA) Still Has Room to Grow
In a report released yesterday, Rick Schafer from Oppenheimer maintained a Buy rating on Nvidia (NVDA – Research Report), with
Oppenheimer Believes IAC/InterActive (NASDAQ: IAC) Won’t Stop Here
In a report released yesterday, Jason Helfstein from Oppenheimer assigned a Buy rating to IAC/InterActive (IAC – Research Report), with
Raymond James Remains a Buy on Antares Pharma (ATRS)
In a report released today, Elliot Wilbur from Raymond James maintained a Buy rating on Antares Pharma (ATRS – Research
Biogen (BIIB) Gets a Sell Rating from Raymond James
In a report released today, Steven Seedhouse from Raymond James maintained a Sell rating on Biogen (BIIB – Research Report).